A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
Brian S. Barnett, Willie O. Siu, Harrison G. Pope
The Journal of Nervous and Mental Disease May 17, 2018 DOI: 10.1097/nmd.0000000000000828 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Survey Peer reviewed |
|---|---|
| Sample size | 324 |
| Population | Members of the American Psychiatric Association (resident-fellows and attending psychiatrists) |
| Topics | Psilocybin |
| Keywords | Hallucinogen |
| Citations | 114 |
| Key findings | A large minority of American psychiatrists expressed optimism about the potential use of hallucinogens for psychiatric treatment, with male and trainee respondents showing less concern and greater optimism. |
Abstract
Recent years have seen renewed interest and research about the use of hallucinogens as possible agents in the treatment of psychiatric disorders. However, we are unaware of studies assessing the current attitudes of American psychiatrists regarding hallucinogens. Therefore, we e-mailed surveys to 1000 members of the American Psychiatric Association-250 resident-fellows and 750 attending psychiatrists. The response rate was 32.4%. Respondents tended to perceive hallucinogens as potentially hazardous and appropriately illegal for recreational purposes. However, a large minority expressed optimism about the potential use of hallucinogens for psychiatric treatment. Male and trainee respondents, as compared with female and attending respondents, reported less concern about the risks of hallucinogens and greater optimism about their therapeutic potential. Younger psychiatrists also seemed more optimistic. Optimism among trainees and younger psychiatrists may possibly reflect greater exposure to recent positive publications about hallucinogens and less awareness of more negative past reports.
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cited by 107
- Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States Journal of Psychoactive Drugs September 1, 2021
- Psychedelic perceptions: mental health service user attitudes to psilocybin therapy Irish Journal of Medical Science June 15, 2021
- Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey Journal of Psychoactive Drugs August 19, 2021
- United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. International Journal of Drug Policy 2022
- Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice Psychedelic Medicine February 16, 2023
and 102 more in the library
Cites 19
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
and 14 more in the library